Filing Flows › Krystal Biotech (KRYS) › Q2 2025
Krystal Biotech (KRYS) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 4, 2025
Krystal Biotech (KRYS) reported revenue of $96.0M for the second quarter 2025 (Q2 2025), +37% from a year earlier and +9% from the quarter before. Operating margin was 41.0%, net earnings $38.3M (39.9% of revenue).
Krystal Biotech, Q2 2025: revenue $96.0M (+37% year over year), operating margin 41.0%, net earnings $38.3M, operating cash flow $52.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $96.0M | +9% | +37% |
| Operating profit | $39.4M | +9% | +360% |
| Net earnings | $38.3M | +7% | +146% |
| Operating cash flow | $52.7M | +70% | — |
| Free cash flow | $50.8M | +105% | — |
What changed
Revenue was $96.0M in Q2 2025, up 37% year over year and up 9% from the previous quarter.
Operating profit was $39.4M, a 41.0% margin (up 28.8 points year over year). Of the extra revenue versus a year earlier, 120% reached operating profit, above the 12% margin then. Total costs fell 8% while revenue rose 37%. The fastest-growing cost line was SG&A (+27%). Net earnings were $38.3M, up 146% year over year. The effective tax rate was 18.0%.
Operating cash flow was $52.7M, 138% of net earnings. Non-cash charges added back $1.3M of depreciation and $14.1M of share-based compensation. Capital expenditures of $1.9M left free cash flow of $50.8M.
Questions
What was Krystal Biotech's revenue in the second quarter 2025?
Krystal Biotech (KRYS) reported revenue of $96.0M for the second quarter 2025 (Q2 2025), +37% from a year earlier and +9% from the quarter before.
Was Krystal Biotech profitable in the second quarter 2025?
Operating profit was $39.4M (41.0% of revenue) and net earnings $38.3M.
Source: Krystal Biotech 10-Q on SEC EDGAR.